Literature DB >> 16303067

Chronic herpes simplex virus type-2 infection and HIV viral load.

W A Duffus1, J Mermin, R Bunnell, R H Byers, G Odongo, P Ekwaru, R Downing.   

Abstract

By December 2003, the estimated adult HIV/AIDS prevalence rate in sub-Saharan Africa was 7.5-8.5%, and rates of herpes simplex virus type-2 (HSV-2) infection among adults aged >30 years ranged from 60% to 82%. However, little is known about the natural history of HIV/HSV-2 co-infection in this population. We evaluated HIV viral load and CD4+ cell counts among persons with and without chronic HSV-2 co-infection in a cross-sectional study of HIV-infected persons not receiving antiretroviral therapy. HSV-2 and HIV co-infection was associated with a 0.3 log copies/mL higher HIV viral load compared with persons without HSV-2 infection (P=0.014). Chronic HSV-2 infection may have a negative effect on the clinical course of persons with HIV.

Entities:  

Mesh:

Year:  2005        PMID: 16303067     DOI: 10.1258/095646205774763298

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  24 in total

1.  The epidemiology of herpes simplex virus type-2 infection among married women in Mysore, India.

Authors:  Purnima Madhivanan; Karl Krupp; Varalakshmi Chandrasekaran; Chitra Karat; Anjali Arun; Jeffrey D Klausner; Arthur L Reingold
Journal:  Sex Transm Dis       Date:  2007-11       Impact factor: 2.830

Review 2.  The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis.

Authors:  Ruanne V Barnabas; Emily L Webb; Helen A Weiss; Judith N Wasserheit
Journal:  AIDS       Date:  2011-08-24       Impact factor: 4.177

Review 3.  A strategy for selecting sexual partners believed to pose little/no risks for HIV: serosorting and its implications for HIV transmission.

Authors:  Lisa A Eaton; Seth C Kalichman; Daniel A O'Connell; William D Karchner
Journal:  AIDS Care       Date:  2009-10

Review 4.  Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.

Authors:  Joshua T Schiffer; Sami L Gottlieb
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

Review 5.  Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.

Authors:  Ruanne V Barnabas; Connie Celum
Journal:  Curr HIV Res       Date:  2012-04       Impact factor: 1.581

6.  Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection.

Authors:  Pedro M M Mesquita; Paula Preston-Hurlburt; Marla J Keller; Nalini Vudattu; Lilia Espinoza; Michelle Altrich; Kathryn Anastos; Kevan C Herold; Betsy C Herold
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

7.  Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study).

Authors:  Ruanne V Barnabas; Judith N Wasserheit; Yunda Huang; Holly Janes; Rhoda Morrow; Jonathan Fuchs; Karen E Mark; Martin Casapia; Devan V Mehrotra; Susan P Buchbinder; Lawrence Corey
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

8.  Lack of association of herpes simplex virus type 2 seropositivity with the progression of HIV infection in the HERS cohort.

Authors:  Brooke E Hoots; Michael G Hudgens; Stephen R Cole; Caroline C King; Robert S Klein; Kenneth H Mayer; Anne M Rompalo; Jack D Sobel; Denise J Jamieson; Jennifer S Smith
Journal:  Am J Epidemiol       Date:  2011-03-03       Impact factor: 4.897

9.  MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa.

Authors:  Giulia Calenda; Guillermo Villegas; Patrick Barnable; Claudia Litterst; Keith Levendosky; Agegnehu Gettie; Michael L Cooney; James Blanchard; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova
Journal:  J Acquir Immune Defic Syndr       Date:  2017-03-01       Impact factor: 3.731

Review 10.  The potential role of biomarkers in HIV preventive vaccine trials.

Authors:  Ellen Maclachlan; Kenneth H Mayer; Ruanne Barnabas; Jorge Sanchez; Beryl Koblin; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.